Quest Diagnostics Incorporated — Q1 2024 Form 10-Q
Business context and period. This unaudited quarterly report covers the three months ended March 31, 2024, compared with Q1 2023. Quest provides diagnostic information services (DIS), which generated 97% of revenue; its other businesses are grouped as Diagnostic Solutions (DS). Amounts below are in millions unless stated otherwise.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $2,366 | $2,331 | +1.5% |
| Operating income | $300 | $305 | -1.7% |
| Operating margin | 12.7% | 13.1% | -0.4 percentage points |
| Net income attributable to Quest | $194 | $202 | -3.9% |
| Diluted EPS | $1.72 | $1.78 | -3.4% |
| Operating cash flow | $154 | $94 | +$60 |
| Capital expenditures | $104 | $127 | -$23 |
DIS revenue grew 1.7% to $2,298; requisition volume rose 1.6% and revenue per requisition rose 0.1%. Excluding COVID-19 testing, base-business DIS revenue, including acquisitions, increased 6.1%; volume increased 3.3% and revenue per requisition increased 2.6%. Acquisitions contributed approximately 0.7% to DIS revenue. DS revenue declined 5.0% to $68. Cost of services rose 2.3%, faster than revenue, while SG&A was essentially flat. Net interest expense increased $8, primarily reflecting the November 2023 issuance of $750 million of 6.40% senior notes due 2033.
Net cash from operations improved year over year, primarily due to lower performance-based compensation payments and the timing of income tax payments. Cash and cash equivalents were $474 at March 31, down from $686 at year-end. Investing cash outflow was $213, including $142 for acquisitions; financing cash outflow was $153. The company paid $79 in dividends during the quarter.
Balance sheet and liquidity
Total debt was approximately $4,710 at March 31 ($906 current and $3,804 long-term), compared with $4,713 at December 31. The current classification includes $600 of 3.50% senior notes due March 2025. Quest repaid $300 of 4.25% notes at maturity on April 1, 2024. The company reported $1.2 billion of available borrowing capacity under its credit facilities, with no borrowings outstanding at quarter-end; $73 of letters of credit were outstanding. Management stated that cash, operating cash flow and available borrowing capacity should fund expected requirements for the foreseeable future. The company was in compliance with applicable financial covenants.
Outlook, management commentary, risks and unusual items
- Quest estimates approximately $420 of 2024 capital expenditures. It provided no specific full-year revenue or earnings guidance in the supplied filing text.
- The multi-year Invigorate program targets 3% annual cost savings and productivity improvements, intended partly to offset inflation, labor and benefit costs, and reimbursement pressures. Management cited automation and AI, operational efficiencies, fewer denials and improved digital experience as focus areas.
- Q1 restructuring and integration charges totaled $17 pretax, including $6 of employee separation costs; most are expected to be cash expenditures, and additional charges may occur. Separately, the financial statements report $6 of restructuring charges, with the remaining disclosed program charges primarily related to integration and facility closures.
- Management identified higher supplies, wages and benefit costs as pressures on service costs, partly offset by Invigorate savings. COVID-19 testing declines partly offset underlying business growth.
- Items reduced Q1 diluted EPS by a net $0.32: $0.19 for intangible amortization, $0.12 for restructuring and integration charges, and $0.03 for contingent-consideration remeasurement, partly offset by $0.02 of excess stock-compensation tax benefits.
- Legal matters include pending class actions and government inquiries, including matters relating to the AMCA data incident, ReproSource data incident, alleged online privacy practices, and other investigations. Management said material legal losses were not probable at March 31, but outcomes may affect results or cash flows. Professional and general liability reserves were $166; the company notes estimates involve significant judgment and actual liabilities could exceed reserves or insurance.
- Management identified reimbursement, billing and revenue-recognition complexity, competition, regulatory changes, customer and supplier relationships, litigation and investigations among factors that could cause future results to differ from expectations.
Important facts for investors to verify
- Whether DIS volume and base-business growth continue, and how much reported growth depends on acquisitions or is offset by falling COVID-19 testing.
- Whether pricing, test mix and productivity gains can offset wage, benefit, supply and reimbursement pressures and support operating margins.
- Cash conversion and working-capital trends, including accounts receivable and days sales outstanding, which were 50 days versus 47 a year earlier.
- Funding plans for the March 2025 $600 note maturity, the April 2024 repayment, and the planned $420 of 2024 capital expenditures.
- Progress toward Invigorate savings and the scale and timing of further restructuring or integration costs.
- Developments in pending legal, privacy and professional-liability matters, including any changes to reserves or expected exposure.